Vector Science & Therapeutics Appoints Darryl Drake Jr. as President of Valor

Vector Science & Therapeutics Corp. (TSXV: PAIN) today announced the appointment of Darryl Drake Jr. as President of Valor and Chairman of the Athletic Board of Directors. Valor is a newly formed ...

Vector Science and Therapeutics Announces Listing on the TSX Venture Exchange

Canadian Public Market Listing Positions Vector Science and Therapeutics to Advance Biomechanical and Localized Drug Delivery Innovation. Vancouver, British Columbia--(Newsfile Co ...

Vector Science & Therapeutics Corp. Grants Options as Company Advances Growth Strategy

Vector Science & Therapeutics (TSXV: PAIN) ("Vector" or the "Company") today announced that the Board of Directors has approved the grant of 206,610 stock options (the "Options") to certain directors ...
Morningstar

Vector Science & Therapeutics Agrees to an Option to Invest in LyoGenesis Plus, Securing Long-Term Access to FDA-Registered, cGMP Manufacturing

Option agreement Supports Vector's Entry into the $80.8 Billion Peptide Market with 22 Novel Pharmaceutical-Grade Formulations MEQUON, Wis., May 13, 2026 /PRNewswire/ -- Vector Science & Therapeutics ...
Morningstar

Vector Science & Therapeutics Announces Tommy Thompson as Chairman of the Board

Former Wisconsin Governor and U.S. Secretary of Health and Human Services Brings Extensive Healthcare Leadership to Pioneer of Transdermal Drug Delivery Technology MEQUON, Wis., April 30, 2026 ...
Newswire

Vector Science & Therapeutics Agrees to an Option to Invest in LyoGenesis Plus, Securing Long-Term Access to FDA-Registered, cGMP Manufacturing

Option agreement Supports Vector's Entry into the $80.8 Billion Peptide Market with 22 Novel Pharmaceutical-Grade Formulations FDA-Registered, cGMP Manufacturing-- MPP operates a modern 35,000 sq. ft.